Skip to main content
LungLife AI, INC logo

LungLife AI, INC — Investor Relations & Filings

Ticker · LLAI ISIN · USU5500L1045 LEI · 549300VBVDIF0Y3OVI38 IL Human health and social work activities
Open in API
Filings indexed 85 across all filing types
Latest filing 2022-11-15 Regulatory Filings
Country US United States of America
Listing IL LLAI

About LungLife AI, INC

https://lunglifeai.com

LungLife AI, INC. is a diagnostic company focused on developing clinical solutions for the early detection of lung cancer. Its principal product, the LungLB® test, is a minimally invasive liquid biopsy that analyzes biomarkers from a simple blood draw. Enhanced by artificial intelligence and machine learning, the test is designed to provide clinicians with additional information to aid in the evaluation and management of indeterminate lung nodules. The company's objective is to improve clinical decision-making and facilitate earlier diagnosis, thereby impacting patient outcomes for the deadliest form of cancer globally.

Recent filings

Filing Released Lang Actions
Block Listing Six Monthly Return
Regulatory Filings Classification · 98% confidence The document is a 'Block Listing Six Monthly Return' filed by LungLife AI, Inc. via the London Stock Exchange's RNS service. This type of filing reports on the issuance of shares under specific stock incentive plans over a six-month period. Since it details changes in share capital and issuance under incentive schemes, it falls under the category of share issues or capital changes.
2022-11-15 English
Director share purchases
Director's Dealing Classification · 100% confidence The document is an official notification of share purchases by company directors (CEO Paul Pagano and CFO David Anderson). It explicitly uses the regulatory language 'Notification of transactions by Directors, Persons Discharging Managerial Responsibilities' and provides the required disclosure details (price, volume, date, and ISIN). This falls directly under the 'Director's Dealing' category.
2022-11-03 English
Participation in National Cancer Institute’s EDRN
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's 'Reach' service, which is explicitly identified as a non-regulatory news service for corporate announcements. The content details a partnership between LungLife AI and the US National Cancer Institute's Early Detection Research Network. Since it does not fit into specific categories like financial reports, board changes, or dividend notices, and is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous corporate news.
2022-10-17 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-year Report' for LungLife AI, Inc. for the six months ended 30 June 2022. It contains comprehensive financial statements, including the Statement of Comprehensive Income, Statement of Financial Position, and Statement of Changes in Equity, along with management commentary. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-26 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from LungLife AI notifying the market of the upcoming release of their interim results and an associated investor presentation. It does not contain the actual financial results or the presentation slides themselves, but rather provides the date and registration details for the event. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2022-09-09 English
New York State approval for commercial testing
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces that LungLife AI has received a CLEP permit from the New York State Department of Health. This is a corporate announcement regarding operational/regulatory progress rather than a financial report, dividend notice, or management change. Since it does not fit into the specific categories like M&A, capital changes, or director dealings, it falls under the general regulatory announcement category.
2022-09-02 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.